Speakers - Sachs Associates
Speakers - Sachs Associates
Speakers - Sachs Associates
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
CONTACT<br />
Juhani Lahdenperä<br />
Chief Executive Officer<br />
ADDRESS<br />
Hermo Pharma Ltd.<br />
Viikinkaari 4<br />
00790 Helsinki<br />
Finland<br />
TELEPHONE<br />
+35 85 0366 9502<br />
EMAIL<br />
lahdenpera@hermopharma.com<br />
YEAR FOUNDED<br />
2008<br />
Hermo Pharma Ltd<br />
www.hermopharma.com<br />
FINANCIAL SUMMARY<br />
Not publicly available.<br />
COMPANY PROFILE<br />
Hermo Pharma Ltd is a clinical stage biopharmaceutical company discovering and developing cuttingedge<br />
therapeutic products and approaches for currently untreatable medical needs in the field of neurology.<br />
Company’s headquarter is located in Helsinki, Finland. The company outsources the majority of operational R&D<br />
tasks to external vendors, while controlling the key technology assets and strategic partnerships.<br />
The company’s R&D programs are based on scientifically innovative concepts. These concepts are being<br />
developed by the company through preclinical and clinical Phase II proof-of-principal trials and after that Hermo<br />
Pharma will seek partnerships to support Phase III trials and market its products worldwide. Currently Hermo<br />
Pharma’s product development focus is on novel disease-modifying treatments for amblyopia in adults and<br />
Parkinson’s disease.<br />
Amblyopia in Adults. The project is currently in Phase IIa clinical trials and the results seems very promising.<br />
Company is expecting to out-license this product latest in early 2014.<br />
Parkinson´s Disease. Company is currently finalizing the pre-clinical proof-of-concepts studies with the support<br />
of M.J.Fox Foundation financing. The therapy is based on the neuroprotective and restorative effects provided by<br />
the CDNF protein. The clinical strategy includes of testing of intracrainial delivery platform to treat the patients.<br />
The current data looks very promising and the company is expecting to proceed into the IND enabling Toxicology<br />
phase during year 2013.<br />
MANAGEMENT<br />
Juhani Lahdenperä, CEO<br />
Henri Huttunen, CSO<br />
Sigrid Booms, Head of Clinical Development<br />
Board of Directors<br />
Jonathan Knowles,<br />
Timo Veromaa,<br />
Ari-Pekka Laitsaari,<br />
Henri Huttunen<br />
Jyrki Mattila<br />
Scientific Advisory Board<br />
Eero Castrén<br />
Mart Saarma<br />
Mary Baker<br />
Seppo Kaakkola<br />
Lamberto Maffei<br />
Heikki Rauvala<br />
Pekka Männistö.<br />
t back :: next u<br />
WELCOME PHARMA LICENSING GROUPS<br />
SPEAKERS<br />
PRESENTING COMPANIES SUPPORTING ORGANISATIONS<br />
ORGANISERS
Change language